Abstract:Context: Pituitary adenoma is a clinical syndrome in which excessive production of pituitary corticotropin (ACTH). For ACTH tumor cells, researchers know little about the influence of the cell-cycle process on ACTH production and cell proliferation. Some research has shown that imatinib can induce apoptosis of tumor cells. Objective: The study intended to explore the effects and molecular mechanisms of imatinib combined with everolimus on AtT-20 cells in AtT-20 mouse pituitary tumors. Design: The research team performed a laboratory study using murine corticotropin tumor AtT-20 cells. Setting: The study took place at the Department of Neurosurgery at Renmin Hospital of the Hubei University of Medicine in Shiyan, Hubei, China. Intervention: The research team cultured the cells in AtT-20-cell-specific medium containing 100 μg/mL of streptomycin, 100 U/mL of penicillin, and 10% fetal bovine serum at 37°C and 5% CO2. The team divided the cells into a control group, a normal culture without the drug, and an intervention group, incubated for 24 hours with 1 μM of imatinib and 3 μM of everolimus when the cells grew to 40% confluence. Outcome measures: The research team: (1) determined the effects of the combined drugs on cell viability using a methyl thiazolyl tetrazolium (MTT) assay; (2) detected the cell's mitochondrial membrane potential and LDH leakage using "sytox blue, 5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide," CBIC2(3) or JC-1, and lactate dehydrogenase (LDH) assay kits, respectively; (3) detected AtT-20 cell apoptosis using a "terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick-end labeling" (TUNEL) kit; (4) analyzed the expression of protein kinase B (p-Akt), cAMP-response element binding protein (p-CREB), p27, p53, and cyclin E using a Western blot test; (5) detected the mRNA expression of opioid melanin procorticotropin (POMC)), caspase-3, and pituitary tumor transforming gene 1 (PTTG1) using reverse transcription-polymerase chain reaction (RT-PCR); (6) measure the concentration of adreno-cortico-tropic-hormone (ACTH) in the supernatant using an enzyme-linked immunoassay (ELISA) kit; and (7) assessed the cell cycle distribution using flow cytometry. Results: No differences existed in cell viability between the groups at the baseline (0 h) of the culture period (P > .05). Compared to the control group, the intervention group's: (1) cell viability was significantly lower at 4, 8, and 12 hours and postintervention at 16 hours (P < .001); (2) LDH concentration was significantly higher (P < .001); (3) mitochondrial membrane potential was significantly lower (P < .001); (4) apoptosis rate of TUNEL was significantly higher (P < .001 ); (5) expression of p-Akt, p-CREB phosphorylation, and cyclin E was significantly lower (P < .001), (6) expression of p27 and p53 protein was significantly higher (P < .001); (7) mRNA expression of POMC and PTTG1 were significantly lower (P < .001); (8) mRNA expression of caspase-3 was significantly higher (P < .001); (9) concentration of ACTH was lower (P < .001); and (10) percentage of cells in the G0/G1 phase was significantly higher, while the percentage of cells in the S phase was significantly lower (P < .05). Conclusions: Imatinib combined with everolimus can affect the AtT-20 cell cycle through the signaling pathway of the phosphatidylin-ositol-3-kinase (PI3K)/Akt/ protein kinase A (PKA) system and can inhibit cell proliferation and induce cell apoptosis. Therefore, Imatinib and everolimus may be an effective combination of candidates for drugs for mouse pituitary tumor.

[Effect of Tyrosine Kinase Inhibitor Imatinib Mesylate on Proliferation, Differentiation and Apoptosis of Kasumi-1 Leukemia Cell Line].

Berbamine Exhibits Potent Antitumor Effects on Imatinib-Resistant CML Cells in Vitro and in Vivo

The Antiproliferation Effect of Berbamine on K562 Resistant Cells by Inhibiting NF‐κB Pathway

[ITF-2357 on Inhibition Myeloid Leukemic Cell Lines Cells Proliferation in Vitro and Its Mechanism].

A Phase Ii Study of Imatinib for Advanced Melanoma Patients with Kit Aberrations

Inhibitory Effect of 4-Chlorobenzoyl Berbamine on Imatinib-Resistant K562 Cells in Vitro and in Vivo

Enhanced Proliferation Inhibition and Apoptosis in Glioma Cells Elicited by Combination of Irinotecan and Imatinib

Efficacy and safety of Imatinib in the 78 patients with advanced melanoma harboring KIT mutation

Effect of Phenylbutyrate, a Histone Deacetylase Inhibitor, on Differentiation and Apoptosis of Kasumi-1 Cells

Overexpression of PlK-1 gene effects of PlK-1 gene on the chemotherapeutic sensitivity of pancreatic carcinoma cell line AsPC-1 response to gemcitabine

Effect of Gemcitabine on Proliferation, Apoptosis and Polo-Like Kinase-1 Expression of Pancreatic Cancer Cell Line AsPC-1

Tyrosine Kinase Inhibitor Imatinib Mesylate Induces Generalized Skin Hypopigmentation in Chinese Patients with Chronic Myelogenous Leukemia.

Effects of Imatinib Combined With Everolimus on Mouse Pituitary Tumor Cell AtT-20

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence from a Retrospective Study

Inhibitory Effects of Imatinib Mesylate on Human Epidermal Melanocytes.

Effect of GSK-3β on Proliferation and Invasion of Endometrioid Adenocarcinoma

[Effect of ADAM10 Inhibitor GI254023X on Proliferation and Apoptosis of Acute T-Lymphoblastic Leukemia Jurkat Cells in Vitro and Its Possible Mechanisms].

Lycorine attenuated proliferation and induced apoptosis on imatinib-resistant K562 cell by inhibiting autophagy

[Effect of Selinexor on Proliferation and Apoptosis of Acute Myeloid Leukemia Kasumi-1 Cells]

Imatinib inhibits oral squamous cell carcinoma by suppressing the PI3K/AKT/mTOR signaling pathway

[The Heat Shock Protein 90 Inhibitor Induces Apoptosis and Differentiation of Kasumi-1 and Its Mechanisms].